JTC Employer Solutions Trustee Ltd Sells 399,462 Shares of GSK plc (NYSE:GSK)

JTC Employer Solutions Trustee Ltd lowered its stake in GSK plc (NYSE:GSK - Free Report) by 1.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,480,962 shares of the pharmaceutical company's stock after selling 399,462 shares during the period. GSK accounts for 54.5% of JTC Employer Solutions Trustee Ltd's portfolio, making the stock its largest position. JTC Employer Solutions Trustee Ltd owned 0.99% of GSK worth $837,364,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of GSK. Aaron Wealth Advisors LLC raised its position in shares of GSK by 11.3% during the third quarter. Aaron Wealth Advisors LLC now owns 20,711 shares of the pharmaceutical company's stock worth $847,000 after acquiring an additional 2,103 shares during the last quarter. Cardinal Capital Management increased its position in GSK by 1.5% in the third quarter. Cardinal Capital Management now owns 56,372 shares of the pharmaceutical company's stock worth $2,326,000 after purchasing an additional 808 shares during the period. Global Retirement Partners LLC raised its holdings in GSK by 4.3% during the 3rd quarter. Global Retirement Partners LLC now owns 40,110 shares of the pharmaceutical company's stock worth $1,640,000 after purchasing an additional 1,664 shares during the last quarter. Good Life Advisors LLC lifted its position in GSK by 90.1% during the 3rd quarter. Good Life Advisors LLC now owns 14,486 shares of the pharmaceutical company's stock valued at $592,000 after purchasing an additional 6,864 shares during the period. Finally, Roberts Wealth Advisors LLC boosted its stake in shares of GSK by 2.1% in the 3rd quarter. Roberts Wealth Advisors LLC now owns 85,376 shares of the pharmaceutical company's stock valued at $3,246,000 after purchasing an additional 1,760 shares during the last quarter. Institutional investors own 15.74% of the company's stock.

Insider Buying and Selling

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 10.00% of the stock is currently owned by company insiders.

GSK Trading Down 1.1 %

GSK stock traded down $0.41 during mid-day trading on Friday, hitting $38.55. 3,728,344 shares of the company's stock were exchanged, compared to its average volume of 3,740,418. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $79.89 billion, a P/E ratio of 13.96, a PEG ratio of 1.30 and a beta of 0.65. The company's 50 day simple moving average is $41.44 and its 200-day simple moving average is $41.26.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The company had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. On average, equities analysts anticipate that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were given a dividend of $0.3843 per share. This is an increase from GSK's previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.54 annualized dividend and a dividend yield of 3.99%. GSK's dividend payout ratio is currently 55.80%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Barclays upgraded shares of GSK to a "hold" rating in a report on Tuesday, August 27th. Argus upgraded GSK to a "strong-buy" rating in a research report on Wednesday, August 7th. Jefferies Financial Group upped their price objective on GSK from $52.50 to $53.00 and gave the company a "buy" rating in a report on Tuesday, July 2nd. UBS Group lowered GSK from a "buy" rating to a "neutral" rating in a research note on Monday, July 8th. Finally, Citigroup upgraded GSK to a "strong-buy" rating in a research report on Monday, June 24th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.